GlassScriptPhysician profile
Rehan Ahmad
NPI 1215959457
$107,532.17
in general payments reported to CMS, 2019-2025
50 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,493 · 2021: $11K · 2022: $14K · 2023: $10K · 2024: $22K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Food and Beverage: $8,776 · Travel and Lodging: $6,906 · Consulting Fee: $350 · Education: $42.50 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,062.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,923.00 |
| Food and Beverage | $8,776.26 |
| Travel and Lodging | $6,905.62 |
| Consulting Fee | $350.00 |
| Education | $42.50 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $70,936.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $18,452.49 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbott Laboratories | $7,277.04 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Insulinx |
| Antares Pharma, INC. | $1,539.84 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $1,439.77 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Amgen INC. | $838.75 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.10 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Corcept Therapeutics | $505.92 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $491.37 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $483.15 | 2021-2025 | |
| Insulet Corporation | $472.04 | 2019-2025 | Omnipod |
| Abbvie INC. | $420.30 | 2019-2024 | Synthroid |
| Mannkind Corporation | $327.08 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $321.03 | 2021-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $292.21 | 2021-2025 | Isturisa, Signifor Lar |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.